Eton Pharmaceuticals, Inc. (ETON) NASDAQ
25.04
+0.61(+2.50%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
25.04
+0.61(+2.50%)
Currency In USD
| Previous Close | 24.43 |
| Open | 24.81 |
| Day High | 25.07 |
| Day Low | 24.33 |
| 52-Week High | 27.29 |
| 52-Week Low | 13.09 |
| Volume | 276,247 |
| Average Volume | 359,003 |
| Market Cap | 683.2M |
| PE | -147.29 |
| EPS | -0.17 |
| Moving Average 50 Days | 20.4 |
| Moving Average 200 Days | 17.75 |
| Change | 0.61 |
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
GlobeNewswire Inc.
Mar 03, 2026 9:30 PM GMT
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced tha
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
GlobeNewswire Inc.
Mar 02, 2026 12:27 PM GMT
HEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initia
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
GlobeNewswire Inc.
Feb 25, 2026 6:47 PM GMT
DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to b